Why the study?
Does fondaparinux improve clinical outcomes and reduce bleeding compared to enoxaparin in patients with NSTEACS?
Does fondaparinux improve clinical outcomes and reduce bleeding compared to enoxaparin in patients with NSTEACS?
Fondaparinux is a preferred anticoagulant for NSTEACS due to its favorable efficacy-to-safety profile, significantly reducing bleeding complications compared to enoxaparin without compromising ischemic protection.
May warrant fondaparinux consideration in NSTE-ACS; leaves open need for updated meta-analyses with contemporary regimens.
Anticoagulation treatment is a vital component of acute coronary syndrome treatment. Selection of the most efficient and safe drug for the acute coronary syndrome patients without ST elevation (NSTEACS) depends on the strategy of treatment and is in fact a difficult task. Fondaparinux (Arixtra) is a synthetic Xa factor clotting inhibitor, has showed its benefits in clinical studies, according to which it is included into clinical guidelines. Current review focuses on the main results and conclusions of the studies, and the place for fondaparinux in clinical practice is described
No takes yet. Share an insight, caveat, or question.
Mardaryan et al. (2015) conducted a review in Non-ST-elevation acute coronary syndrome (n=20,078). Fondaparinux vs. Enoxaparin was evaluated on Death, myocardial infarction, or refractory ischemia at 9 days (HR 1.01, 95% CI 0.90-1.13, p=0.007).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: